Which disease-relevant molecular pathways and gene-network modules most plausibly drive Chronic kidney disease (fibrosis) initiation and progression, and what causal experiments (e.g., perturbation, s

Summary
Chronic kidney disease (CKD) and renal fibrosis are driven by a convergence of defective fatty acid oxidation (FAO), maladaptive developmental signaling (TGF-β/Smad, Wnt, Notch), and the activation of specific inflammatory macrophage modules (S100A8/A9+, Notch-NF-κB). Causal validation requires cell-specific genetic perturbations (e.g., tubule or macrophage-specific knockouts) integrated with spatial transcriptomics to delineate the "fibrotic niche" where immune-stromal-epithelial crosstalk occurs.

Primary Molecular Pathways Driving Fibrosis

1. Tubular Metabolic Reprogramming (FAO/PGC-1α Axis)

• Mechanism: Healthy renal tubular epithelial cells (TECs) rely on mitochondrial fatty acid oxidation (FAO) as their primary energy source (Direct; PMID: 25419705, PMID: 35680856). In fibrotic kidneys, enzymes and regulators of FAO (CPT1A, PPARA, PPARGC1A) are significantly downregulated, leading to intracellular lipid accumulation, mitochondrial dysfunction, and an ATP energy crisis (Direct; PMID: 25419705, PMID: 41566544).
• Initiation: This metabolic shift occurs early, potentially predating the expression of fibrotic markers (Direct; PMID: 25419705). Transforming growth factor-beta 1 (TGF-β1) suppresses FAO in a Smad3-dependent manner by transcriptionally inhibiting PPARGC1A (Direct; PMID: 25419705).
• Progression: Reduced FAO triggers a "Warburg-like" switch to glycolysis, which promotes cellular senescence, G2/M cell cycle arrest, and the secretion of pro-fibrotic factors such as FGF2 and TGF-β (Derived; PMID: 25419705, PMID: 35491858, PMID: 41648789).

2. Developmental Signaling and Immuno-Fibrotic Coupling

• TGF-β/Smad Signaling: This is the canonical central pathway (Direct; PMID: 36932062). Smad3 promotes myofibroblast activation and extracellular matrix (ECM) synthesis while inhibiting matrix metalloproteinases (Direct; PMID: 34112221, PMID: 34999158).
• Wnt/β-catenin and Notch Pathways: Re-activation of these embryonic pathways drives TEC dedifferentiation and fibroblast-to-myofibroblast transition (Direct; PMID: 36932062, PMID: 34999158). Wnt/β-catenin signaling specifically controls the release of osteopontin-enriched exosomes from tubules to activate fibroblasts (Direct; PMID: 36932062).
• Inflammatory Macrophage Modules: A unique monocyte-derived macrophage population characterized by S100a8/S100a9 expression arrives early (within 2 hours of injury) to initiate and amplify renal inflammation via TLR4-NF-κB signaling (Direct; PMID: 35112806). Additionally, excessive Notch activation in macrophages drives M1-like polarization and promotes renal tubular necroptosis (Direct; PMID: 35280997).

3. Epigenetic and "Hypoxic Memory" Modules

• Epigenetic Imprinting: CKD involves stable reprogramming of gene expression through DNA methylation (e.g., hypermethylation of RASAL1 and KLOTHO) and histone modifications (e.g., loss of H3K27me3 at pro-fibrotic loci) (Direct; PMID: 41607591, PMID: 36932062).
• Memory Modules: "Metabolic memory" and "hypoxic memory" allow pathological gene expression to persist even after the initial stimulus (e.g., hyperglycemia or ischemia) is resolved, creating a physical and functional barrier to tissue repair (Direct; PMID: 41607591, PMID: 36932062).

Prioritized Causal Experiments for Validation

To move beyond association, the research landscape suggests the following prioritization for experimental validation:

1. Cell-Specific Perturbation (The Gold Standard)

• Prioritize: Using inducible Cre-Lox systems (e.g., Pax8-rtTA for tubules, LysM-Cre or Ms4a3-Cre for monocyte-derived macrophages) to knock out or overexpress key nodal genes like Atg5, Cpt1a, or Notch1 (Direct; PMID: 37463911, PMID: 25419705, PMID: 35112806, PMID: 38968801).
• Rationale: This establishes whether a pathway in a specific cell type is necessary and sufficient for fibrosis. For example, overexpressing Cpt1a in tubules was shown to be sufficient to restore mitochondrial function and reverse fibrosis (Direct; PMID: 25419705).

2. Spatial Profiling and "Niche" Identification

• Prioritize: Integration of single-cell RNA sequencing (scRNA-seq) with spatial transcriptomics (e.g., Visium, Stereo-seq) to map the "fibrotic niche" (Direct; PMID: 36932062, PMID: 38968801, PMID: 41716409).
• Rationale: Fibrosis does not occur uniformly. Mapping the physical proximity of injured VCAM-1+ tubules to activated fibroblasts and S100A8/A9+ macrophages identifies essential paracrine signaling hubs (e.g., the SPP1-CD44 axis) (Derived; PMID: 36932062, PMID: 41710901).

3. Multi-Omics Integration for Mechanism Decoding

• Prioritize: Integrating snATAC-seq (chromatin accessibility) with snRNA-seq to identify core transcription factors (e.g., BACH1, RXRα) driving the transition to maladaptive repair states (Direct; PMID: 41607591).
• Rationale: This distinguishes between transient transcriptional changes and stable epigenetic reprogramming (memory modules) that define CKD chronicity (Derived; PMID: 41607591).

Evidence Quality and Limitations

• Evidence Quality: Strong for tubular metabolic defects (PMID: 25419705) and canonical TGF-β/Wnt signaling (PMID: 36932062). Moderate for specific immune-cell-origin impacts (PMID: 35112806, PMID: 38968801).
• Limitations: Many mechanistic insights are derived from acute models (e.g., UUO or IRI) that may not fully recapitulate the slow, multifactorial progression of human CKD (PMID: 41521814, PMID: 36932062). Causal proof for "hypoxic memory" in humans remains technically challenging due to limited access to longitudinal biopsies (PMID: 41607591).